https://fecri.org.au/publication/efficacy-and-safety-of-maintenance-therapy-with-pamiparib-versus-placebo-for-advanced-gastric-cancer-responding-to-first-line-platinum-based-chemotherapy-phase-2-study-results/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/the-interleukin-11-il-11-receptor-promotes-glioblastoma-survival-and-invasion-under-glucose-starved-conditions-through-enhanced-glutaminolysis/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/low-dose-palliative-chemotherapy-compared-to-standard-dose-chemotherapy-for-poor-prognosis-cancers-improves-overall-survival-a-single-institution-study/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/sphingosine-1-phosphate-receptor-5-s1pr5-regulates-the-peripheral-retention-of-tissue-resident-lymphocytes/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/prognostic-role-of-immune-checkpoint-regulators-in-cholangiocarcinoma-a-pilot-study/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/when-langerhans-met-crohn-intestinal-inflammation-in-disguise/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/foxp3-tregs-from-langerhans-cell-histiocytosis-lesions-co-express-cd56-and-have-a-definitively-regulatory-capacity/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/accuracy-and-prognostic-significance-of-oncologists-estimates-and-scenarios-for-survival-time-in-advanced-gastric-cancer/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/altered-populations-of-unconventional-t-cell-lineages-in-patients-with-langerhans-cell-histiocytosis/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/a-potentially-important-role-for-t-cells-and-regulatory-t-cells-in-langerhans-cell-histiocytosis/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/health-related-quality-of-life-associated-with-regorafenib-treatment-in-refractory-advanced-gastric-adenocarcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/knockdown-of-stem-cell-regulator-oct4a-in-ovarian-cancer-reveals-cellular-reprogramming-associated-with-key-regulators-of-cytoskeleton-extracellular-matrix-remodeling/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/early-treatment-intensification-with-r-ice-and-90y-ibritumomab-tiuxetan-zevalin-beam-stem-cell-transplantation-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-and-positive-interim-pet-after/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer-cancer/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/evaluation-of-response-from-axitinib-per-response-evaluation-criteria-in-solid-tumors-versus-choi-criteria-in-previously-treated-patients-with-metastatic-renal-cell-carcinoma/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/observation-versus-late-reintroduction-of-letrozole-as-adjuvant-endocrine-therapy-for-hormone-receptor-positive-breast-cancer-anz0501-later-an-open-label-randomised-controlled-trial/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/resolution-of-norfloxacin-induced-acute-liver-failure-after-n-acetylcysteine-therapy-further-support-for-the-use-of-nac-in-drug-induced-alf/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/anastrozole-versus-tamoxifen-for-the-prevention-of-locoregional-and-contralateral-breast-cancer-in-postmenopausal-women-with-locally-excised-ductal-carcinoma-in-situ-ibis-ii-dcis-a-double-blind-ra/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/suppression-subtractive-hybridization-method-for-the-identification-of-a-new-strain-of-murine-hepatitis-virus-from-xenografted-scid-mice/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/eversun-a-phase-2-trial-of-alternating-sunitinib-and-everolimus-as-first-line-therapy-for-advanced-renal-cell-carcinoma/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/polyclonal-t-cells-express-cd1a-in-langerhans-cell-histiocytosis-lch-lesions/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/adjuvant-exemestane-with-ovarian-suppression-in-premenopausal-breast-cancer/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/axitinib-versus-sorafenib-in-advanced-renal-cell-carcinoma-subanalyses-by-prior-therapy-from-a-randomised-phase-iii-trial/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/neoadjuvant-chemotherapy-with-sequential-anthracycline-docetaxel-with-gemcitabine-for-large-operable-or-locally-advanced-breast-cancer-anz-0502-neogem/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/long-term-effects-of-continuing-adjuvant-tamoxifen-to-10-years-versus-stopping-at-5-years-after-diagnosis-of-oestrogen-receptor-positive-breast-cancer-atlas-a-randomised-trial/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/breast-cancer-adjuvant-therapy-with-zoledronic-acid/2026-06-12T04:49:39+00:00https://fecri.org.au/publication/adjuvant-trastuzumab-in-her2-positive-breast-cancer/2026-06-12T04:49:50+00:00https://fecri.org.au/publication/a-cryptic-deletion-in-5q31-2-provides-further-evidence-for-a-minimally-deleted-region-in-myelodysplastic-syndromes/2026-06-12T04:49:50+00:00https://fecri.org.au/publication/the-severe-chronic-neutropenia-international-registry-10-year-follow-up-report/2026-06-12T04:49:50+00:00https://fecri.org.au/publication/neutrophil-elastase-mutations-and-risk-of-leukaemia-in-severe-congenital-neutropenia/2026-06-12T04:49:50+00:00https://fecri.org.au/publication/three-cases-of-activation-of-cutaneous-squamous-cell-carcinoma-during-treatment-with-prolonged-administration-of-rituximab/2026-06-12T04:49:50+00:00https://fecri.org.au/publication/the-incidence-of-leukemia-and-mortality-from-sepsis-in-patients-with-severe-congenital-neutropenia-receiving-long-term-g-csf-therapy/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/severe-chronic-neutropenia-treatment-and-follow-up-of-patients-in-the-severe-chronic-neutropenia-international-registry/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/a-time-to-kill-viral-manipulation-of-the-cell-death-program/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/glycogen-storage-disease/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/mutations-in-the-gene-encoding-neutrophil-elastase-in-congenital-and-cyclic-neutropenia/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/myelodysplasia-syndrome-and-acute-myeloid-leukemia-in-patients-with-congenital-neutropenia-receiving-g-csf-therapy/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/novel-endogenous-type-d-retroviral-particles-expressed-at-high-levels-in-a-scid-mouse-thymic-lymphoma/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/perivascular-t-cells-express-the-pro-inflammatory-chemokine-rantes-mrna-in-multiple-sclerosis-lesions/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/leukemia-inhibitory-factor-and-interleukin-6-are-produced-by-diseased-and-regenerating-skeletal-muscle/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/ews-fli-1-fusion-transcript-detection-and-mic2-immunohistochemical-staining-in-the-diagnosis-of-ewings-sarcoma/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/cytogenetic-and-dna-analysis-of-two-neuroectodermal-tumors-without-a-simple-t1122/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/soluble-antigen-can-cause-enhanced-apoptosis-of-germinal-centre-b-cells/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/bcl-2-transgene-expression-can-protect-neurons-against-developmental-and-induced-cell-death/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/viable-bone-marrow-stromal-cells-are-required-for-the-in-vitro-survival-of-b-cell-precursor-acute-lymphoblastic-leukemic-cells/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/flow-cytometric-analysis-of-intercellular-adhesion-between-b-cell-precursor-acute-lymphoblastic-leukemic-cells-and-bone-marrow-stromal-cells/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/kiz-1-a-protein-with-lim-zinc-finger-and-kinase-domains-is-expressed-mainly-in-neurons/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/the-role-of-cytokines-in-the-pathogenesis-of-langerhans-cell-histiocytosis/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/the-biology-of-erythropoietin-and-its-role-in-the-anaemia-of-prematurity/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/human-bone-marrow-stromal-cell-contact-and-soluble-factors-have-different-effects-on-the-survival-and-proliferation-of-paediatric-b-lineage-acute-lymphoblastic-leukaemic-blasts/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/dose-intensive-cyclophosphamide-with-etoposide-and-vincristine-for-paediatric-solid-tumors-a-phase-i-ii-pilot-study-by-the-australia-and-new-zealand-childhood-cancer-study-group/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/measurement-of-the-growth-parameters-of-precursor-b-acute-lymphoblastic-leukaemic-cells-in-co-culture-with-bone-marrow-stromal-cells-detection-of-two-cd10-positive-populations-with-different-prolifer/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/a-novel-approach-to-the-measurement-of-different-in-vitro-leukaemic-cell-growth-parameters-the-use-of-pkh-gl-fluorescent-probes/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/characterization-of-stroma-adherent-colony-forming-cells-a-clonogenic-assay-for-early-hemopoietic-cells/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/scl-gene-in-human-tumors/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/proliferative-properties-of-unfractionated-purified-and-single-cell-human-progenitor-populations-stimulated-by-recombinant-human-interleukin-3/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/effects-of-recombinant-human-granulocyte-colony-stimulating-factor-on-hematopoietic-progenitor-cells-in-cancer-patients/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/enhancement-of-in-vitro-beta-thalassemic-and-normal-hematopoiesis-by-a-noncytotoxic-monoclonal-antibody-9-1c3-evidence-for-negative-regulation-of-hematopoiesis-by-monocytes-and-natural-killer-cells/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/pharmacokinetics-of-human-granulocyte-macrophage-colony-stimulating-factor-using-a-sensitive-immunoassay/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/clinical-studies-with-granulocyte-colony-stimulating-factor-g-csf-in-patients-receiving-cytotoxic-chemotherapy/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/activated-killer-cell-lymphoma-an-erythrophagocytic-syndrome-simulating-histiocytic-medullary-histiocytosis/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/clonal-proliferation-in-vitro-of-individual-murine-and-human-hemopoietic-cells-after-fluorescence-activated-cell-sorting/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/evidence-for-interactions-between-monocytes-and-natural-killer-cells-in-the-regulation-of-in-vitro-hemopoiesis/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/fractionation-of-subsets-of-bfu-e-from-normal-human-bone-marrow-responsiveness-to-erythropoietin-human-placental-conditioned-medium-or-granulocyte-macrophage-colony-stimulating-factor/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/a-human-complement-fixing-monoclonal-anti-human-lymphocyte-antibody-of-rat-origin/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/fractionation-of-normal-and-beta-thalassemic-human-hemopoietic-progenitor-cells-by-immunomagnetic-beads/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/transgenic-mice-expressing-a-hemopoietic-growth-factor-gene-gm-csf-develop-accumulations-of-macrophages-blindness-and-a-fatal-syndrome-of-tissue-damage/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/studies-by-radioiodination-of-normal-adult-fetal-and-leukemic-cell-membranes/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/osmotic-fragility-of-leukaemic-and-normal-lymphocytes/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/crosstalk-between-immune-checkpoint-modulators-metabolic-reprogramming-and-cellular-plasticity-in-triple-negative-breast-cancer-2/2026-06-12T04:49:51+00:00https://fecri.org.au/publication/aberrant-pregnancy-associated-plasma-protein-a-expression-in-breast-cancers-prognosticates-clinical-outcomes-2/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/abs-11-patterns-of-use-of-adjuvant-therapy-in-patients-with-stage-1-nsgct/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/identifying-and-targeting-determinants-of-melanoma-cellular-invasion/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/efficacy-and-toxicity-of-treatment-with-the-anti-ctla-4-antibody-ipilimumab-in-patients-with-metastatic-melanoma-after-prior-anti-pd-1-therapy/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/transketolase-like-1-ectopic-expression-is-associated-with-dna-hypomethylation-and-induces-the-warburg-effect-in-melanoma-cells/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/updated-efficacy-and-toxicity-of-treatment-with-the-anti-ctla-4-antibody-ipilimumab-in-metastatic-melanoma-patients-previously-treated-with-anti-pd-1-therapy/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/embryonic-chicken-transplantation-is-a-promising-model-for-studying-the-invasive-behavior-of-melanoma-cells/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/effect-of-pregnant-sera-and-a-pregnancy-associated-metalloproteinase-papp-a-on-melanoma-in-vitro-and-in-vivo-insights-into-melanoma-progression-during-pregnancy-and-potential-new-therapeutic-target/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/patterns-of-use-of-adjuvant-therapy-in-patients-with-stage-1-nsgct/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/determinants-of-resistance-to-vegf-tki-and-immune-checkpoint-inhibitors-in-metastatic-renal-cell-carcinoma-5/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/in-vitro-and-in-silico-analysis-of-epithelial-mesenchymal-transition-and-cancer-stemness-as-prognostic-markers-of-clear-cell-renal-cell-carcinoma-3/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/platinum-resistance-in-epithelial-ovarian-cancer-an-interplay-of-epithelial-mesenchymal-transition-interlinked-with-reprogrammed-metabolism-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/expression-of-timps-and-mmps-in-ovarian-tumours-ascites-ascites-derived-cells-and-cancer-cell-lines-characteristic-modulatory-response-before-and-after-chemotherapy-treatment-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/adjuvant-ovarian-suppression-in-premenopausal-breast-cancer-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/timp-2-regulates-proliferation-invasion-and-stat3-mediated-cancer-stem-cell-dependent-chemoresistance-in-ovarian-cancer-cells-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/in-vitro-and-in-vivo-toxicity-and-biodistribution-of-paclitaxel-loaded-cubosomes-as-a-drug-delivery-nanocarrier-a-case-study-using-an-a431-skin-cancer-xenograft-model/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/ovarian-cancer-cancer-stem-cells-and-current-treatment-strategies-a-potential-role-of-magmas-in-the-current-treatment-methods-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/the-potential-role-of-interleukin-11-in-epithelial-ovarian-cancer/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/paclitaxel-induced-src-activation-is-inhibited-by-dasatinib-treatment-independently-of-cancer-stem-cell-properties-in-a-mouse-model-of-ovarian-cancer-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/tumour-microenvironment-and-metabolic-plasticity-in-cancer-and-cancer-stem-cells-perspectives-on-metabolic-and-immune-regulatory-signatures-in-chemoresistant-ovarian-cancer-stem-cells-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/paclitaxel-loaded-self-assembled-lipid-nanoparticles-as-targeted-drug-delivery-systems-for-the-treatment-of-aggressive-ovarian-cancer/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/momelotinib-decreased-cancer-stem-cell-associated-tumor-burden-and-prolonged-disease-free-remission-period-in-a-mouse-model-of-human-ovarian-cancer-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/the-many-facets-of-metzincins-and-their-endogenous-inhibitors-perspectives-on-ovarian-cancer-progression-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/surface-profiling-of-extracellular-vesicles-from-plasma-or-ascites-fluid-using-dotscan-antibody-microarrays-chapter-20/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/coalition-of-oct4a-and-%ce%b21-integrins-in-facilitating-metastasis-in-ovarian-cancer-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/molecular-pathways-regulating-epidermal-growth-factor-induced-epithelio-mesenchymal-transition-in-human-ovarian-surface-epithelium/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/unique-proteome-signature-of-post-chemotherapy-ovarian-cancer-ascites-derived-tumor-cells-2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/assessing-the-carcinogenic-potential-of-low-dose-exposures-to-chemical-mixtures-in-the-environment-the-challenge-ahead/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/a-critical-role-of-oct4a-in-mediating-metastasis-and-disease-free-survival-in-a-mouse-model-of-ovarian-cancer/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/enhanced-activation-of-stat3-in-ascites-derived-recurrent-ovarian-tumors-inhibition-of-cisplatin-induced-stat3-activation-reduced-tumorigenicity-of-ovarian-cancer-by-a-loss-of-cancer-stem-cell-like-c/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/distinct-molecular-signature-of-recurrent-ovarian-tumor-cells-isolated-from-the-ascites-of-advanced-stage-serous-ovarian-cancer-patients/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/betaglycan-blocks-metastatic-behaviors-in-human-granulosa-cell-tumors-by-suppressing-nfkb-mediated-induction-of-mmp2/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/targeted-disruption-of-jak2-stat3-pathway-in-combination-with-systemic-administration-of-paclitaxel-inhibits-the-priming-of-ovarian-cancer-stem-cells-leading-to-a-reduced-tumor-burden/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/inhibition-of-the-jak2-stat3-pathway-in-ovarian-cancer-results-in-the-loss-of-cancer-stem-cell-like-characteristics-and-a-reduced-tumor-burden/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/granulocyte-colony-stimulating-factor-receptor-signalling-via-janus-kinase-2-signal-transducer-and-activator-of-transcription-3-in-ovarian-cancer/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/ovarian-cancer-stem-cells-molecular-concepts-and-relevance-as-therapeutic-targets/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/short-term-single-treatment-of-chemotherapy-results-in-the-enrichment-of-ovarian-cancer-stem-cell-like-cells-leading-to-an-increased-tumor-burden/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/getting-to-know-ovarian-cancer-ascites-opportunities-for-targeted-therapy-based-translational-research/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/cancerous-ovarian-stem-cells-obscure-targets-for-therapy-but-relevant-to-chemoresistance/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/investigation-of-human-cationic-antimicrobial-protein-18-hcap-18-lactoferrin-and-cd163-as-potential-biomarkers-for-ovarian-cancer/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/attributes-of-oct4-in-stem-cell-biology-perspectives-on-cancer-stem-cells-of-the-ovary/2026-06-12T04:49:21+00:00https://fecri.org.au/publication/isolation-and-characterization-of-tumor-cells-from-the-ascites-of-ovarian-cancer-patients-molecular-phenotype-of-chemo-resistant-ovarian-tumors/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/contribution-of-fibroblast-and-mast-cell-afferent-and-tumor-efferent-il-6-effects-within-the-tumor-micro-environment/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/cisplatin-treatment-of-primary-and-metastatic-epithelial-ovarian-carcinomas-generates-residual-cells-with-mesenchymal-stem-cell-like-profiles/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/2d-page-of-ovarian-cancer-analysis-of-soluble-and-insoluble-fractions-using-narrow-ph-ranges/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/effect-of-silencing-neutrophil-gelatinase-associated-lipocalin-in-ovarian-cancer-cells-on-epithelio-mesenchymal-transition/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/multicellular-spheroids-in-ovarian-cancer-metastases-biology-and-pathology/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/neuronal-transcription-factor-brn-3a-is-over-expressed-in-high-grade-ovarian-carcinomas-and-tumor-cells-from-ascites-of-patients-with-advanced-stage-ovarian-cancer/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/epidermal-growth-factor-induced-ovarian-carcinoma-cell-migration-is-associated-with-jak2-stat3-signals-and-changes-in-the-abundance-and-localization-of-a6b1-integrin/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/cross-talk-of-signals-between-egfr-and-il-6r-via-jak2-stat3-mediate-epithelial-mesenchymal-transition-in-ovarian-carcinomas/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/epithelial-mesenchymal-interconversions-in-normal-ovarian-epithelium-and-ovarian-carcinomas-an-exception-to-the-norm/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/immunohistochemical-perspective-of-pparb-and-one-of-its-putative-targets-pdk1-in-normal-ovaries-benign-and-malignant-ovarian-tumours/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/neutrophil-gelatinase-associated-lipocalin-ngal-an-early-screening-biomarker-for-ovarian-cancer-ngal-is-associated-with-epidermal-growth-factor-induced-epithelio-mesenchymal-transition/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/a2b1-integrin-affects-metastatic-ability-of-ovarian-carcinoma-spheroids-by-supporting-disaggregation-and-proteolysis/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/proteomics-tracking-of-serum-protein-isoforms-as-screening-biomarkers-of-ovarian-cancer/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/role-of-integrin-receptors-for-fibronectin-collagen-and-laminin-in-the-regulation-of-ovarian-carcinoma-functions-in-response-to-a-matrix-micro-environment/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/ascites-induces-modulation-of-a6-integrin-and-urokinase-plasminogen-activator-receptor-expression-and-associated-functions-in-ovarian-carcinoma/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/translational-proteomics-developing-a-predictive-capacity/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/strategies-for-revealing-lower-abundance-proteins-in-two-dimensional-protein-maps/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/enhanced-expression-of-peroxisome-proliferator-receptor-g-expression-in-ovarian-carcinoma/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/proteomics-based-identification-of-hatoglobin-1-precursor-as-a-novel-circulating-biomarker-for-ovarian-cancer/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/cell-free-59-kda-immunoreactive-integrin-linked-kinase-a-novel-marker-for-ovarian-carcinoma/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/expression-and-localization-of-avb6-integrin-in-extraplacental-fetal-membranes-possible-role-in-human-parturition/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/integrin-linked-kinase-expression-increases-with-ovarian-tumour-grade-and-is-sustained-by-peritoneal-tumour-fluid/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/down-regulation-of-urokinase-plasminogen-activator-expression-inhibits-erk-signaling-with-concomitant-suppression-of-matrix-metalloprotease-9-mmp-9-due-to-loss-of-upar-b1-integrin-complex-in-colon-c/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/proteomic-profiling-of-proteins-associated-with-urokinase-plasminogen-activator-receptor-upar-in-colon-cancer-cells-using-an-antisense-approach/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/avb6-integrin-a-marker-for-the-malignant-potential-of-epithelial-ovarian-cancer/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/integrin-expression-in-colon-cancer-cells-is-regulated-by-the-cytoplasmic-domain-of-the-b6-integrin-subunit/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/direct-integrin-avb6-erk-binding-implications-for-tumour-growth/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/overexpression-of-avb6-integrin-in-serous-epithelial-ovarian-cancer-regulates-extracellular-matrix-degradation-via-the-plasminogen-activation-cascade/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/the-avb6-integrin-regulates-its-own-expression-with-cell-crowding-implications-for-tumor-progression/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/ceramides-that-mediate-apoptosis-reduce-glucose-uptake-and-transporter-affinity-for-glucose-in-human-leukaemic-cell-lines-but-not-in-neutrophils/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/distinct-regulation-of-glucose-transport-by-interleukin-3-and-oncogenes-in-a-murine-bone-marrow-derived-cell-line/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/n-glycosylation-of-glucose-transporter-1-glut-1-is-associated-with-increased-transporter-affinity-for-glucose-in-human-leukemic-cells/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/il-3-induces-apoptosis-differential-effect-of-il-3-on-the-survival-and-growth-response-of-parental-and-oncogene-transfected-cells/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/transforming-oncogenes-regulate-glucose-transport-by-increasing-transporter-affinity-for-glucose-contrasting-effects-of-oncogenes-and-heat-stress-in-a-murine-bone-marrow-derived-cell-line/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/telomerase-activity-in-a-specific-cell-subset-coexpressing-integrin-b1-egfr-but-not-p75ngfr-bcl2-in-normal-human-epithelial-cell/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/acute-regulation-of-glucose-transport-after-activation-of-human-peripheral-blood-neutrophils-by-phorbol-myristate-acetate-fmlp-and-granulocyte-macrophage-colony-stimulating-factor/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/acute-regulation-of-glucose-transport-in-a-monocyte-macrophage-cell-line-glut-3-activity-for-glucose-is-enhanced-during-the-respiratory-burst/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/regulation-of-glucose-transport-by-interleukin-3-in-growth-factor-dependent-and-oncogene-transformed-bone-marrow-derived-cell-lines/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/the-hemopoietic-growth-factor-interleukin-3-promotes-glucose-transport-by-increasing-the-specific-activity-and-maintaining-the-affinity-for-glucose-of-plasma-membrane-glucose-transporters-in-a-bone/2026-06-12T04:49:37+00:00https://fecri.org.au/publication/interaction-of-reactive-nitrogen-and-oxygen-intermediates-in-hl60-and-dimethyl-sulphoxide-differentiated-hl60-cells/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/biochemical-effect-of-three-different-inhibitors-of-purine-pyrimidine-metabolism-on-differentiation-in-hl60-cells/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/purine-metabolism-in-promyelocytic-hl60-and-dimethyl-sulphoxide-differentiated-hl60-cells/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/glycolytic-glutaminolytic-and-pentose-phosphate-pathways-in-promyelocytic-hl60-and-dmso-differentiated-hl60-cells/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/the-human-promyelocytic-hl60-cell-line-a-model-of-myeloid-cell-differentiation-using-dimethylsulphoxide-phorbol-ester-and-butyrate/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/oral-cholera-vaccines-containing-b-subunit-killed-whole-cells-and-whole-cells-only-cross-reacting-antigens-of-the-members-of-family-vibrionaceae-and-the-vaccines/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/the-impact-of-low-dose-carcinogens-and-environmental-disrupters-on-tissue-invasion-and-metastasis/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/the-role-of-pregnancy-associated-plasma-protein-a-in-triple-negative-breast-cancer-a-promising-target-for-achieving-clinical-benefits-3/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/cd73-and-pd-l1-as-potential-therapeutic-targets-in-gallbladder-cancer-2/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/combined-inhibition-of-tgf-%ce%b21-induced-emt-and-pd-l1-silencing-re-sensitizes-hepatocellular-carcinoma-to-sorafenib-treatment-3/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/immune-checkpoint-molecules-are-regulated-by-transforming-growth-factor-tgf-%ce%b21-induced-epithelial-to-mesenchymal-transition-in-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/tnf-%ce%b1-mediated-epithelial-to-mesenchymal-transition-regulates-expression-of-immune-checkpoint-molecules-in-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/spotlight-on-bortezomib-potential-in-the-treatment-of-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/monitoring-immune-checkpoint-regulators-as-predictive-biomarkers-in-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/evaluation-of-the-glypican-3-promoter-for-transcriptional-targeting-of-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/seek-and-destroy-targeted-adeno-associated-viruses-for-gene-delivery-to-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/promoter-hypomethylation-of-ny-eso-1-association-with-clinicopathological-features-and-pd-l1-expression-in-non-small-cell-lung-cancer/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/murine-hepatocellular-carcinoma-derived-stem-cells-reveal-epithelial-to-mesenchymal-plasticity/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/epithelial-to-mesenchymal-transition-a-mediator-of-sorafenib-resistance-in-advanced-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/two-photon-dual-imaging-platform-for-in-vivo-monitoring-cellular-oxidative-stress-in-liver-injury/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/epithelial-to-mesenchymal-plasticity-of-cancer-stem-cells-therapeutic-targets-in-hepatocellular-carcinoma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/dual-targeting-of-bromodomain-and-extraterminal-domain-proteins-and-wnt-or-mapk-signaling-inhibits-c-myc-expression-and-proliferation-of-colorectal-cancer-cells/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/pregnancy-associated-plasma-protein-a-links-pregnancy-and-melanoma-progression-by-promoting-cellular-migration-and-invasion-2/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/foxp3-over-expression-inhibits-melanoma-tumorigenesis-via-effects-on-proliferation-and-apoptosis/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/transgelin-is-a-direct-target-of-tgf-beta-smad3-dependent-epithelial-cell-migration-in-lung-fibrosis/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/leukocytes-induce-epithelial-to-mesenchymal-transition-after-unilateral-ureteral-obstruction-in-neonatal-mice/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/mouse-models-of-glioma/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/the-role-of-tim-3-in-glioblastoma-progression/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/metabolic-plasticity-of-glioblastoma-cells-in-response-to-dhodh-inhibitor-bay2402234-treatment/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/microgel-based-bioink-for-extrusion-based-3d-bioprinting-and-its-applications-in-tissue-engineering/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/supramolecular-guest-exchange-in-cucurbit7uril-for-bioorthogonal-fluorogenic-imaging-across-the-visible-spectrum/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/use-of-suppression-subtractive-hybridization-for-viral-diagnostics-2/2026-06-19T05:38:52+00:00https://fecri.org.au/publication/advances-in-crispr-cas-systems-based-cell-and-gene-therapy/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/knock-down-of-timp-2-by-sirna-and-crispr-cas9-mediates-diverse-cellular-reprogramming-of-metastasis-and-chemosensitivity-in-ovarian-cancer-4/2026-06-12T04:49:38+00:00https://fecri.org.au/publication/current-development-of-monoclonal-antibodies-in-cancer-therapy/2026-06-12T04:49:06+00:00https://fecri.org.au/publication/global-conformational-changes-in-igg-fc-upon-mutation-of-the-fcrn-binding-site-are-not-associated-with-altered-antibody-dependent-effector-functions/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/cross-species-analysis-of-fc-engineered-anti-lewis-y-human-igg1-variants-in-human-neonatal-receptor-transgenic-mice-reveal-importance-of-s254-and-y436-in-binding-human-neonatal-fc-receptor/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/glyceride-lipid-formulations-molecular-dynamics-modeling-of-phase-behavior-during-dispersion-and-molecular-interactions-between-drugs-and-excipients/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/using-molecular-dynamics-to-study-liquid-phase-behavior-simulations-of-the-ternary-sodium-laurate-sodium-oleate-water-system/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/does-cd1a-expression-influence-t-cell-function-in-patients-with-langerhans-cell-histiocytosis-2/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/langerhans-cell-histiocytosis-a-malignant-myeloid-neoplasm-or-disorder-of-immune-regulation-2/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/co-expression-of-cd56-and-production-of-transforming-growth-factor-beta-by-foxp3-regulatory-t-cells-from-langerhans-cell-histiocytosis-lesions/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/the-role-of-t-cells-in-the-immune-regulation-of-langerhans-cell-histiocytosis-lch/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/consumption-of-a-low-glycaemic-index-diet-in-late-life-extends-lifespan-of-balb-c-mice-with-differential-effects-on-dna-damage/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/thymic-development-of-unconventional-t-cells-how-nkt-cells-mait-cells-and-%ce%b3%ce%b4-t-cells-emerge/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/high-cd26-and-low-cd94-expression-identifies-an-il-23-responsive-v%ce%b42-t-cell-subset-with-a-mait-cell-like-transcriptional-profile/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/a-role-for-mait-cells-in-colorectal-cancer-2/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/chronically-stimulated-human-mait-cells-are-unexpectedly-potent-il-13-producers-2/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/temporal-regulation-of-natural-killer-t-cell-interferon-gamma-responses-by-%ce%b2-catenin-dependent-and-independent-wnt-signaling/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/human-blood-mait-cell-subsets-defined-using-mr1-tetramers/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/experimental-and-human-evidence-for-lipocalin-2-neutrophil-gelatinase-associated-lipocalin-ngal-in-the-development-of-cardiac-hypertrophy-and-heart-failure/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/a-three-stage-intrathymic-development-pathway-for-the-mucosal-associated-invariant-t-cell-lineage/2026-06-12T04:49:19+00:00https://fecri.org.au/publication/an-emerging-role-for-immune-regulatory-subsets-in-chronic-lymphocytic-leukaemia-2/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/natural-killer-t-cells-drivers-or-passengers-in-preventing-human-disease/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/the-glucocorticoid-receptor-1a3-promoter-correlates-with-high-sensitivity-to-glucocorticoid-induced-apoptosis-in-human-lymphocytes/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/acute-exercise-leads-to-regulation-of-telomere-associated-genes-and-microrna-expression-in-immune-cells-2/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/natural-killer-t-cell-defects-in-multiple-myeloma-and-the-impact-of-lenalidomide-therapy/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/ex-vivo-analysis-of-human-natural-killer-t-cells-demonstrates-heterogeneity-between-tissues-and-within-established-cd4-and-cd4-subsets/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/the-bh3-only-proteins-bim-and-puma-cooperate-to-impose-deletional-tolerance-of-organ-specific-antigens/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/the-nf-%ce%bab1-transcription-factor-prevents-the-intrathymic-development-of-cd8-t-cells-with-memory-properties/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/presumed-guilty-natural-killer-t-cell-defects-and-human-disease/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/lessons-learned-from-an-unusual-presentation-of-cd3-cd56-t-cell-large-granular-lymphocyte-leukemia/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/transcriptional-regulation-of-lymphocyte-development-developing-nkt-cells-need-their-e-protein/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/divergent-satb1-expression-across-human-life-span-and-tissue-compartments/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/testing-the-nkt-cell-hypothesis-in-lenalidomide-treated-myelodysplastic-syndrome-patients/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/an-nzw-derived-interval-on-chromosome-7-moderates-sialadenitis-but-not-insulitis-in-congenic-nonobese-diabetic-mice/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/immune-characterization-of-an-individual-with-an-exceptionally-high-natural-killer-t-cell-frequency-and-her-immediate-family/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/nkt-cell-development-in-the-absence-of-the-autoimmune-regulator-gene-aire/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/diverse-cytokine-production-by-nkt-cell-subsets-and-identification-of-an-il-17-producing-cd4-nk1-1-nkt-cell-population/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/peripheral-nk1-1-nkt-cells-are-mature-and-functionally-distinct-from-their-thymic-counterparts/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/control-points-in-nkt-cell-development/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/retraction-antigen-induced-tolerance-by-intrathymic-modulation-of-self-recognizing-inhibitory-receptors/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/antigen-challenge-inhibits-thymic-emigration/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/long-term-retention-of-mature-nk1-1-nkt-cells-in-the-thymus/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/localization-of-idd11-is-not-associated-with-thymus-and-nkt-cell-abnormalities-in-nod-mice/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/differential-antitumor-immunity-mediated-by-nkt-cell-subsets-in-vivo/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/the-influence-of-cd1d-in-postselection-nkt-cell-maturation-and-homeostasis/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/the-cellular-mechanism-of-aire-control-of-t-cell-tolerance/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/activation-of-thymic-regeneration-in-mice-and-humans-following-androgen-blockade/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/working-with-nkt-cells-pitfalls-and-practicalities/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/limited-correlation-between-human-thymus-and-blood-nkt-cell-content-revealed-by-an-ontogeny-study-of-paired-tissue-samples/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/are-we-really-on-the-right-trail/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/parallels-and-distinctions-between-t-and-nkt-cell-development-in-the-thymus/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/systemic-nkt-cell-deficiency-in-nod-mice-is-not-detected-in-peripheral-blood-implications-for-human-studies/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/antigen-induced-tolerance-by-intrathymic-modulation-of-self-recognizing-inhibitory-receptors/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/normal-thymocyte-negative-selection-in-trail-deficient-mice/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/t-cell-compartments-of-prediabetic-nod-mice/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/thymic-regeneration-teaching-an-old-immune-system-new-tricks/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/projection-of-an-immunological-self-shadow-within-the-thymus-by-the-aire-protein/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/essential-role-for-the-lymphostromal-plasma-membrane-ly-6-superfamily-molecule-thymic-shared-antigen-1-in-development-of-the-embryonic-adrenal-gland/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/a-central-role-for-thymic-emigrants-in-peripheral-t-cell-homeostasis/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/thymic-shared-antigen-2-a-novel-cell-surface-marker-associated-with-t-cell-differentiation-and-activation/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/the-role-of-the-thymus-and-recent-thymic-migrants-in-the-maintenance-of-the-adult-peripheral-lymphocyte-pool/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/expression-of-the-gastric-h-k-atpase-alpha-subunit-in-the-thymus-may-explain-the-dominant-role-of-the-beta-subunit-in-the-pathogenesis-of-autoimmune-gastritis/2026-06-12T04:49:20+00:00https://fecri.org.au/publication/transforming-growth-factor-%ce%b2-in-tumor-microenvironment-understanding-its-impact-on-monocytes-and-macrophages-for-its-targeting/2026-06-12T04:49:06+00:00https://fecri.org.au/publication/goldi-complexes-of-the-type-aulkappac-2-c6h4psph2-l-pta-pph3-pph2c6h4-3-so3na-and-pph22-py-synthesis-characterisation-crystal-structures-and-in-vitro-and-in-viv/2026-06-12T04:49:06+00:00https://fecri.org.au/publication/phase-characterization-and-bioactivity-evaluation-of-nucleic-acid-encapsulated-biomimetically-mineralized-zif-8/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/systemic-brain-dissemination-of-glioblastoma-requires-transdifferentiation-into-endothelial-like-cells-via-tgf-%ce%b2-alk1-smad1-5-signaling/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/advances-in-applications-of-the-crispr-cas9-system-for-respiratory-diseases/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/recent-progress-in-crispr-cas9-system-for-eye-disorders/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/immunomodulatory-properties-of-a-methanolic-extract-of-ficus-lyrata-mitigate-inflammation-in-complete-freunds-adjuvant-induced-arthritis/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/enhanced-expression-of-mitochondrial-magmas-protein-in-ovarian-carcinomas-magmas-inhibition-facilitates-antitumour-effects-signifying-a-novel-approach-for-ovarian-cancer-treatment/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/proteomic-effects-of-colchicine-on-human-macrophages-loaded-with-oxidised-low-density-lipoprotein-cholesterol/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/protein-disulfide-isomerases-regulate-androgen-receptor-stability-and-promote-prostate-cancer-cell-growth-and-survival/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/mechanistic-insight-into-inflammatory-and-oxidative-stress-ameliorating-attributes-of-atriplex-crassifolia-70-ethanol-extract-against-complete-freunds-adjuvant-induced-arthritis/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/in-silico-and-functional-characterisation-of-nematode-galectin-3-and-galectin-9/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/correlation-of-galectin-family-expression-with-glioblastoma-progression-and-survival/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-new-systemic-disease-mouse-model-for-glioblastoma-capable-of-single-tumour-cell-detection/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/signaling-pathways-underlying-tgf-%ce%b2-mediated-suppression-of-il-12a-gene-expression-in-monocytes/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/molecular-mechanisms-associated-with-the-inhibitory-role-of-long-chain-n-3-pufa-in-colorectal-cancer/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/the-prognostic-value-of-preoperative-inflammatory-markers-for-pathological-grading-of-glioma-patients/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/thymic-development-of-human-natural-killer-t-cells-recent-advances-and-implications-for-immunotherapy/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/herg-channel-agonist-ns1643-strongly-inhibits-invasive-astrocytoma-cell-line-sma-560/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/reduced-t-and-nk-cell-activity-in-glioblastoma-patients-correlates-with-tim-3-and-bat3-dysregulation/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/impact-of-ligand-concentration-on-the-properties-of-nucleic-acid-encapsulated-mofs-and-inflammation-modulation-in-prostate-cancer-cells/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/tryptophan-and-substance-abuse-mechanisms-and-impact/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/moxonidine-increases-uptake-of-oxidised-low-density-lipoprotein-in-cultured-vascular-smooth-muscle-cells-and-inhibits-atherosclerosis-in-apolipoprotein-e-deficient-mice/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/label-free-macrophage-phenotype-classification-using-machine-learning-methods/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/targeting-telomerase-utilizing-zeolitic-imidazole-frameworks-as-non-viral-gene-delivery-agents-across-different-cancer-cell-types/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/dynamics-of-transforming-growth-factor-%ce%b2-signaling-and-therapeutic-efficacy/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-three-stage-developmental-pathway-for-human-v9v2-t-cells-within-the-postnatal-thymus/2026-06-12T06:05:20+00:00https://fecri.org.au/publication/editorial-non-viral-vectors-for-gene-therapy-nucleic-acid-delivery/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-new-era-of-integration-between-multiomics-and-spatio-temporal-analysis-for-the-translation-of-emt-towards-clinical-applications-in-cancer/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/divergent-molecular-networks-program-functionally-distinct-cd8-skin-resident-memory-t-cells/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/krill-oil-supplementation-reduces-the-growth-of-ct-26-orthotopic-tumours-in-balb-c-mice-jayathilake-ag-kadife-e-kuol-n-luwor-rb-nurgali-k-su-xq/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/the-comparative-anti-cancer-effects-of-krill-oil-and-oxaliplatin-in-an-orthotopic-mouse-model-of-colorectal-cancer/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/extracellular-vesicles-secreted-by-glioma-stem-cells-are-involved-in-radiation-resistance-and-glioma-progression/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/precision-medicine-an-optimal-approach-to-patient-care-in-renal-cell-carcinoma/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/plasma-signaling-factors-in-patients-with-langerhans-cell-histiocytosis-lch-correlate-with-relative-frequencies-of-lch-cells-and-t-cells-within-lesions/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-quest-for-cytocompatible-metal-organic-frameworks-in-non-viral-gene-therapy-relevance-of-zeolitic-imidazolate-framework-8/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-high-dimensional-cytometry-atlas-of-peripheral-blood-over-the-human-life-span/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/blocking-muscarinic-receptor-3-attenuates-tumor-growth-and-decreases-immunosuppressive-and-cholinergic-markers-in-an-orthotopic-mouse-model-of-colorectal-cancer/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/egfrviii-promotes-cell-survival-during-endoplasmic-reticulum-stress-through-a-reticulocalbin-1-dependent-mechanism/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-modified-mts-proliferation-assay-for-suspended-cells-to-avoid-the-interference-by-hydralazine-and-%ce%b2-mercaptoethanol/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/patients-with-both-langerhans-cell-histiocytosis-and-crohns-disease-highlight-a-common-role-of-interleukin-23/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/dual-targeting-of-sorafenib-resistant-hcc-derived-cancer-stem-cells/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/carfilzomib-promotes-the-unfolded-protein-response-and-apoptosis-in-cetuximab-resistant-colorectal-cancer/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/dinuclear-orthometallated-goldi-goldiii-anticancer-complexes-with-potent-in-vivo-activity-through-an-ros-dependent-mechanism/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/the-effects-of-the-dietary-compound-l-sulforaphane-against-respiratory-pathogens/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/association-between-hereditary-hemochromatosis-and-hepatocellular-carcinoma-a-comprehensive-review/2026-06-12T04:49:05+00:00https://fecri.org.au/publication/a-divergent-transcriptional-landscape-underpins-the-development-and-functional-branching-of-mait-cells/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/expression-of-cd38-on-resting-peripheral-inkt-cells-defines-an-immature-subpopulation-with-distinct-functionality-in-humans/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/the-changing-immune-landscape-of-innate-like-t-cells-and-other-innate-cells-throughout-life/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/an-approach-to-remove-albumin-for-the-proteomic-analysis-of-low-abundance-biomarkers-in-human-serum/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/association-between-alphavbeta6-integrin-expression-elevated-p42-44-kda-mapk-and-plasminogen-dependent-matrix-degradation-in-ovarian-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/epithelial-mesenchymal-transition-and-cancer-stem-cell-like-phenotypes-facilitate-chemoresistance-in-recurrent-ovarian-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/immunohistochemistry-and-in-situ-hybridization-of-human-carcinomas/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/safety-and-effectiveness-of-sutimlimab-in-cold-agglutinin-disease-a-real-world-international-experience/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/single-cell-rna-sequence-analysis-reveals-usp32-as-a-therapeutic-target-to-mitigate-pd-l1-driven-colorectal-tumorigenesis-in-vitro-and-in-vivo/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/methanol-extract-of-chenopodium-murale-l-attenuated-tnf-%ce%b1-mediated-oxidative-stress-and-inflammation-in-murine-models/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/effect-of-methanolic-extract-of-salix-babylonica-on-biochemical-parameters-and-gene-expression-in-streptozotocin-induced-diabetic-rat-model/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/parathyroid-hormone-related-protein-and-human-papillomavirus-in-gynecological-tumors/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/identification-of-a-cell-surface-protein-with-a-role-in-stimulating-human-keratinocyte-proliferation-expressed-during-development-and-carcinogenesis/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/pthrp-and-cell-division-expression-and-localization-of-pthrp-in-a-keratinocyte-cell-line-hacat-during-the-cell-cycle/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/mutation-of-a-single-conserved-tryptophan-in-multidrug-resistance-protein-1-mrp1-abcc1-results-in-loss-of-drug-resistance-and-selective-loss-of-organic-anion-transport/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/multiple-membrane-associated-tryptophan-residues-contribute-to-the-transport-activity-and-substrate-specificity-of-the-human-multidrug-resistance-protein-mrp1/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/coronary-artery-disease-why-we-should-consider-the-y-chromosome/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/the-penetration-of-methanol-into-bovine-cardiac-and-hepatic-tissues-is-faster-than-ethanol-and-formalin/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/combination-targeting-of-epithelial-to-mesenchymal-transition-and-immune-checkpoint-molecules-resensitizes-hepatocellular-carcinoma-to-sorafenib-treatment/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/tnf-%ce%b1-promotes-epithelial-to-mesenchymal-transition-and-expression-of-immune-checkpoint-molecules-in-hepatocellular-carcinoma/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/immune-checkpoint-blockade-therapies-for-hcc-current-status-and-future-implications/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/exosome-based-liquid-biopsy-in-the-management-of-hepatocellular-carcinoma/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/immune-checkpoint-inhibitors-and-tumor-mutation-burden-as-predictive-biomarkers-in-hepatocellular-carcinoma/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/papp-a-is-a-marker-of-aggressive-breast-cancer-and-promotes-cancer-progression-in-vitro/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/epithelial-to-mesenchymal-transition-as-a-potential-target-for-antineoplastic-therapies/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/thrombospondin-1-promotes-an-aggressive-phenotype-through-epithelial-to-mesenchymal-transition-in-human-melanoma-3/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/effects-of-epithelial-to-mesenchymal-transition-on-t-cell-targeting-of-melanoma-cells-2/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/thrombospondin-1-is-a-targetable-marker-of-invasive-mesenchymal-like-melanoma-cells/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/effects-of-tgf%ce%b22-on-wild-type-and-tgfbr3-knockout-mouse-fetal-testis/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/fetal-testis-dysgenesis-and-compromised-leydig-cell-function-in-tgfbr3-betaglycan-knockout-mice/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/reducing-betaglycan-expression-by-rna-interference-rnai-attenuates-inhibin-bio-activity-in-l%ce%b2t2-gonadotrope-cells/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/loss-of-betaglycan-contributes-to-the-malignant-properties-of-human-granulosa-tumor-cells/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/transforming-growth-factor-beta-blocks-inhibin-binding-to-different-target-cell-types-in-a-context-dependent-manner-through-dual-mechanisms-involving-betaglycan/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/labour-associated-regulation-of-prostaglandin-e-and-f-synthesis-and-action-in-the-ovine-amnion-and-cervix/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/prostaglandin-e-and-f-receptor-expression-and-myometrial-sensitivity-at-labor-onset-in-the-sheep/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/pituitary-cell-lines-and-their-endocrine-applications/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/changes-in-the-expression-of-prostaglandin-e-and-f-synthases-at-induced-and-spontaneous-labour-onset-in-the-sheep/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/capivasertib-in-hormone-receptor-positive-advanced-breast-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/adjuvant-olaparib-for-patients-with-brca1-or-brca2-mutated-breast-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/overall-survival-in-the-olympia-phase-iii-trial-of-adjuvant-olaparib-in-patients-with-germline-pathogenic-variants-in-brca1-2-and-high-risk-early-breast-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/tailoring-adjuvant-endocrine-therapy-for-premenopausal-breast-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/the-attributes-of-plakins-in-cancer-and-disease-perspectives-on-ovarian-cancer-progression-chemoresistance-and-recurrence-2/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/interleukin-11-il-11-receptor-promotes-glioblastoma-cell-proliferation-epithelial-mesenchymal-transition-and-invasion/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/plakin-expression-in-serous-epithelial-ovarian-cancer-has-the-potential-to-impede-metastatic-spread-and-epithelial-mesenchymal-transition-a-comparative-expression-analysis-of-immunohistochemical-and/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/results-of-the-apml3-trial-incorporating-all-trans-retinoic-acid-and-idarubicin-in-both-induction-and-consolidation-as-initial-therapy-for-patients-with-acute-promyelocytic-leukemia/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/encapsulation-visualization-and-expression-of-genes-with-biomimetically-mineralized-zeolitic-imidazolate-framework%e2%80%908-zif%e2%80%908/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/modulation-of-metal-azolate-frameworks-for-the-tunable-release-of-encapsulated-glycosaminoglycans/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/zif-c-for-targeted-rna-interference-and-crispr-cas9-based-gene-editing-in-prostate-cancer/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/functionalization-of-elongated-tetrahexahedral-au-nanoparticles-and-their-antimicrobial-activity-assay/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/intrinsic-fluorescence-from-cellulose-nanofibers-and-nanoparticles-at-cell-friendly-wavelengths/2026-06-12T04:49:04+00:00https://fecri.org.au/publication/real-time-detection-and-identification-of-nematode-eggs-genus-and-species-through-optical-imaging/2026-06-12T04:49:03+00:00https://fecri.org.au/publication/multimodal-imaging-and-soft-x%e2%80%90ray-tomography-of-fluorescent-nanodiamonds-in-cancer-cells/2026-06-12T04:49:03+00:00https://fecri.org.au/publication/a-novel-gene-delivery-approach-using-metal-organic-frameworks-in-human-islet-derived-progenitor-cells/2026-06-12T04:48:45+00:00https://fecri.org.au/publication/zif-polymorphs-for-nucleic-acid-delivery-and-targeted-knockdown-of-gene-expression-in-prostate-cancer/2026-06-12T04:48:45+00:00https://fecri.org.au/publication/zif-c-as-non-viral-delivery-system-for-crispr-cas9-mediated-htert-knockdown-in-cancer-cells/2026-06-12T04:48:45+00:00https://fecri.org.au/publication/mof-based-nucleic-acid-delivery-for-knockdown-of-gene-expression-in-prostate-cancer/2026-06-12T04:48:45+00:00https://fecri.org.au/publication/monoclonal-antibody-806-inhibits-the-growth-of-tumor-xenografts-expressing-either-the-de2-7-or-amplified-epidermal-growth-factor-receptor-egfr-but-not-wild-type-egfr/2026-06-12T04:48:45+00:00https://fecri.org.au/publication/antitumor-efficacy-of-cytotoxic-drugs-and-the-monoclonal-antibody-806-is-enhanced-by-the-egf-receptor-inhibitor-ag1478/2026-06-12T04:48:45+00:00https://fecri.org.au/publication/the-tumor-specific-de2-7-epidermal-growth-factor-receptor-egfr-promotes-cells-survival-and-heterodimerizes-with-the-wild-type-egfr/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/the-antiepidermal-growth-factor-receptor-monoclonal-antibody-cetuximab-c225-reduces-hypoxia-inducible-factor-1-alpha-leading-to-transcriptional-inhibition-of-vascular-endothelial-growth-factor-expres/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/treatment-of-human-tumor-xenografts-with-monoclonal-antibody-806-in-combination-with-a-prototypical-epidermal-growth-factor-receptor-specific-antibody-generates-enhanced-antitumor-activity/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/enhancement-of-antitumor-activity-of-the-anti-egf-receptor-monoclonal-antibody-cetuximab-c225-by-perifosine-in-pten-deficient-cancer-cells/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/epidermal-growth-factor-receptor-egfr-ubiquitination-as-a-mechanism-of-acquired-resistance-escaping-treatment-by-the-anti-egfr-monoclonal-antibody-cetuximab/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/transforming-growth-factor-beta-tgf-beta-and-brain-tumours/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/the-egfrviii-variant-in-glioblastoma-multiforme/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/antibodies-specifically-targeting-a-locally-misfolded-region-of-tumor-associated-egfr/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/constitutively-active-harvey-ras-confers-resistance-to-epidermal-growth-factor-receptor-targeted-therapy-with-cetuximab-and-gefitinib/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/new-reagents-for-improved-in-vitro-and-in-vivo-examination-of-tgf-%ce%b2-signalling/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/dynamin-ii-function-is-required-for-egf-mediated-stat3-activation-but-not-erk1-2-phosphorylation/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/targeting-stat3-and-smad7-to-restore-tgf-%ce%b2-cytostatic-regulation-of-tumor-cells-in-vitro-and-in-vivo/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/the-role-of-stat3-in-glioblastoma-multiforme/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/glycogen-synthase-kinase-3%ce%b2-gsk-3%ce%b2-and-its-dysregulation-in-glioblastoma-multiforme/2026-06-26T06:20:56+00:00https://fecri.org.au/publication/interleukin-11-is-the-dominant-il-6-family-cytokine-during-gastrointestinal-tumorigenesis-and-can-be-targeted-therapeutically/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/anti-egfr-therapeutic-efficacy-correlates-directly-with-inhibition-of-stat3-activity/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/nuclear-receptor-nr4a1-promotes-breast-cancer-invasion-and-metastasis-by-activating-tgf-%ce%b2-signalling/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/expression-of-the-adaptor-protein-tks5-in-human-cancer-prognostic-potential/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/the-role-of-stat3-signaling-in-mediating-tumor-resistance-to-cancer-therapy/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/single-live-cell-tgf-%ce%b2-signalling-imaging-breast-cancer-cell-motility-and-migration-is-driven-by-sub-populations-of-cells-with-dynamic-tgf-%ce%b2-smad3-activity/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/using-bioluminescence-imaging-in-glioma-research/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/spsb1-a-novel-negative-regulator-of-the-transforming-growth-factor-%ce%b2-signaling-pathway-targeting-the-type-ii-receptor/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/the-peroxisome-proliferator-activated-receptor-gamma-agonist-pioglitazone-increases-functional-expression-of-the-glutamate-transporter-excitatory-amino-acid-transporter-2-eaat2-in-human-glioblastoma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/microrna-as-potential-biomarkers-in-glioblastoma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/mirna-expression-profiling-of-cerebrospinal-fluid-in-patients-with-aneurysmal-subarachnoid-hemorrhage/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/inhibition-of-glioblastoma-cell-proliferation-migration-and-invasion-by-the-proteasome-antagonist-carfilzomib/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/defining-the-essential-function-of-fbp-ksrp-proteins-drosophila-psi-interacts-with-the-mediator-complex-to-modulate-myc-transcription-and-tissue-growth/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/the-emergent-role-of-exosomes-in-glioma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/cancer-exosomes-in-cerebrospinal-fluid/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/stat3-signaling-mediates-tumour-resistance-to-egfr-targeted-therapeutics/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/the-emerging-use-of-bioluminescence-in-medical-research/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/enhancement-of-invadopodia-activity-in-glioma-cells-by-sublethal-doses-of-irradiation-and-temozolomide/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/effects-of-ephb4-receptor-expression-on-colorectal-cancer-cells-tumor-growth-vascularization-and-composition/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/a-comprehensive-meta-analysis-of-circulation-mirnas-in-glioma-as-potential-diagnostic-biomarker/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/peripheral-biomarkers-in-glioblastoma-patients-is-it-all-just-hotair/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/epidermal-growth-factor-receptor-structure-function-informing-the-design-of-anticancer-therapeutics/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/inhibition-of-radiation-and-temozolomide-induced-invadopodia-activity-in-glioma-cells-using-fda-approved-drugs/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/the-role-of-interleukin-6-stat3-signalling-in-glioblastoma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/cell-quiescence-correlates-with-enhanced-glioblastoma-cell-invasion-and-cytotoxic-resistance/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/ponatinib-inhibits-multiple-signaling-pathways-involved-in-stat3-signaling-and-attenuates-colorectal-tumor-growth/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/ponatinib-a-novel-multi-tyrosine-kinase-inhibitor-against-human-malignancies/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/targeting-glioma-stem-cells-by-functional-inhibition-of-dynamin-2-a-novel-treatment-strategy-for-glioblastoma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/potent-and-selective-cytotoxic-and-anti-inflammatory-goldiii-compounds-containing-cyclometalated-phosphine-sulfide-ligands/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/krill-oil-extract-suppresses-the-proliferation-of-colorectal-cancer-cells-through-activation-of-caspase-3-9/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/antitumor-and-antiangiogenic-properties-of-goldiii-complexes-containing-cycloaurated-triphenylphosphine-sulfide-ligands/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/novel-additive-for-sperm-cryopreservation-media-holotheria-parva-coelomic-cavity-extract-protects-human-spermatozoa-against-oxidative-stress-a-pilot-study/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/therapeutic-reversal-of-radiotherapy-injury-to-pro-fibrotic-dysfunctional-fibroblasts-in-vitro-using-adipose-derived-stem-cells/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/serum-microrna-is-a-biomarker-for-post-operative-monitoring-in-glioma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/reduced-egfr-and-increased-mir-221-is-associated-with-increased-resistance-to-temozolomide-and-radiotherapy-in-glioblastoma/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/krill-oil-extract-inhibits-the-migration-of-human-colorectal-cancer-cells-and-down-regulates-egfr-signalling-and-pd-l1-expression/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/elucidating-the-role-of-long-intergenic-non-coding-rna-339-in-human-endometrium-and-endometriosis/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/examination-of-novel-immunomodulatory-effects-of-l-sulforaphane/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/cortical-tension-initiates-the-positive-feedback-loop-between-cadherin-and-f-actin/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/exploring-the-sources-and-potential-applications-of-marine-collagenases/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/model-systems-and-unique-biological-features-of-high-and-low-grade-colorectal-cancer-crc-revealed-by-xenografting-84-human-crc-cell-lines/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/synthetic-biology-for-cancer-stem-cells-chapter-27/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/synthetic-biology-in-precision-medicine-and-nanotechnology-chapter-37/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/recent-developments-in-single-cell-transcriptomics/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/nanotechnology-in-the-generation-and-analysis-of-single-cells/2026-06-26T06:20:55+00:00https://fecri.org.au/publication/interplay-between-immune-checkpoint-modulators-and-the-epithelial-to-mesenchymal-transition-axis-in-clear-cell-renal-cell-carcinoma/2026-07-24T04:42:14+00:00https://fecri.org.au/publication/the-signaling-networks-oftim-3-tgf-%ce%b2-and-sting-in-glioblastoma/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/snai-transcription-factors-mediate-epithelial-mesenchymal-transition-in-lung-fibrosis/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/role-of-cytokine-induced-plasticity-in-melanoma-on-invasive-therapy-resistant-cells-that-express-emt-related-genes-and-pathways/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/ubiquitin-specific-protease-43-promotes-degradation-of-phenylalanine-hydroxylase-in-mammalian-cells/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/pregnancy-associated-plasma-protein-a-drives-melanoma-metastasis-and-immune-evasion-via-igf-signaling/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/enrichment-of-multiple-immune-checkpoints-in-cholangiocarcinoma-cancer-stem-cells/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/attenuation-of-receptor-interacting-protein-kinase-3-ripk3-and-mixed-lineage-kinase-domain-like-pseudokinase-mlkl-blocks-the-trif-ripk3-mlkl-driven-necroptotic-cell-death-in-steatotic-hepatocytes/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/epithelial-to-mesenchymal-transition-as-a-robust-biomarker-and-a-novel-strategy-to-enhance-response-to-immune-checkpoint-blockade-and-targeted-therapy-in-patients-with-metastatic-renal-cell-carcinoma/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/necroptosis-contributes-to-cell-death-of-steatotic-hepatocytes-following-ischaemic-injury/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/h-ferritin-and-iron-activate-inflammatory-pathways-in-adipocytes/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/prognostic-impact-of-immune-checkpoint-inhibitor-expression-and-its-association-with-epithelial-to-mesenchymal-transition-in-hepatocellular-carcinoma/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/evaluation-of-tumor-specific-promoters-for-transcriptional-targeting-of-hepatocellular-carcinoma/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/gene-therapy-targeting-of-choroidal-disease-and-aav-transcytosis-through-the-outer-blood-retina-barrier-epithelium/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/genetic-evidence-for-the-role-of-ultraviolet-radiation-in-the-pathogenesis-of-uveal-melanoma/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/characterizing-and-combating-the-immune-modulatory-and-epithelial-to-mesenchymal-plasticity-properties-of-hepatocellular-carcinoma-derived-cancer-stem-cells/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/in-vivo-quantitative-visualization-of-hypochlorous-acid-in-the-liver-using-a-novel-selective-two-photon-fluorescent-probe/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/thrombospondin-1-promotes-anin-vitroandin-vivoinvasive-phenotype-through-epithelial-to-mesenchymal-transition-in-human-melanoma/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/slow-cycling-melanoma-cells-are-resistant-to-therapy-and-exhibit-a-targetable-emt-related-expression-profile/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/metalloproteinase-pregnancy-associated-plasma-protein-a-papp-a-promotes-melanoma-progression-in-vitro/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/mechanism-of-igf-induced-epithelial-to-mesenchymal-transition-emt-in-melanoma-progression/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/rapid-loss-of-the-alveolar-epithelial-cell-phenotype-during-primary-culture-in-a-matrix-independent-fashion/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/protein-profiling-of-cultured-primary-alveolar-epithelial-type-ii-cells-reveals-a-rapid-loss-of-the-alveolar-phenotype/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/snai-transcription-factors-in-epithelial-to-mesenchymal-transition-comparative-analysis-of-experimental-and-idiopathic-pulmonary-fibrosis/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/snail-and-slug-are-key-mediators-of-tgf-beta-induced-epithelial-to-mesenchymal-transition-in-lung-fibrosis/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/snail-and-slug-as-central-mediators-of-the-tgf-beta-induced-epithelial-to-mesenchymal-transition-emt-in-pulmonary-fibrosis/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/inhibins-differentially-antagonize-activin-and-bone-morphogenetic-protein-action-in-a-mouse-adrenocortical-cell-line/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/new-insights-into-mammalian-sugar-transport-and-its-regulation-at-the-plasma-membrane/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/ovarian-cancer-stem-cells-molecular-concepts-and-relevance-as-therapeutic-targets-2/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/collaboration-of-epithelial-mesenchymal-transition-and-cancer-stem-cells-sinister-routes-for-chemoresistant-recurrent-ovarian-cancer/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/outside-front-coverbiotechnology-journal-3-2021/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/metal-organic-frameworks-mofs-as-non-viral-gene-delivery-vehicles-for-gene-therapy-in-prostate-cancer/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/momelotinib-reduces-cancer-stem-cell-load-leading-to-a-decreased-tumor-burden-and-a-prolonged-disease-free-remission-period-in-a-mouse-model-of-human-ovarian-cancer/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/effects-of-high-and-low-ephb4-receptor-expression-on-colorectal-cancer-cell-behaviour-and-tumour-growth-vascularisation-and-composition/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/growth-suppression-of-intracranial-xenografted-glioblastomas-overexpressing-mutant-epidermal-growth-factor-receptors-by-systemic-administration-of-monoclonal-antibody-mab-806-a-novel-monoclonal-ant/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/murine-hepatitis-virus-rna-complete-genome-strain-mhv-mi/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/a-method-for-the-treatment-of-tumours-and-sarcomas/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/cellular-and-humoral-interactions-in-haemopoiesis/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/characterization-of-interleukin-3-and-granulocyte-macrophage-receptors-on-normal-human-hemopoietic-cells/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/enhanced-expression-of-adamts1-in-ovarian-carcinomas-loss-of-adamts1-expression-instigates-cellular-reprogramming-of-extracellular-matrix-ensuing-altered-plasticity-augmented-migration-and-attenuate-2/2026-06-26T06:20:54+00:00https://fecri.org.au/publication/final-outcomes-of-the-soft-and-text-phase-iii-trials-in-premenopausal-hormone-receptor-positive-early-breast-cancer/2026-06-26T06:20:54+00:00